Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Growth in Short Interest

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 18,930,000 shares, an increase of 7.0% from the October 31st total of 17,690,000 shares. Based on an average daily trading volume, of 747,500 shares, the short-interest ratio is presently 25.3 days.

Karyopharm Therapeutics Trading Up 1.8 %

Shares of KPTI stock traded up $0.01 during trading hours on Tuesday, reaching $0.84. 415,639 shares of the stock were exchanged, compared to its average volume of 1,213,961. The firm has a market capitalization of $105.32 million, a price-to-earnings ratio of -0.72 and a beta of 0.05. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The company's 50-day moving average price is $0.84 and its 200-day moving average price is $0.87.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to analysts' expectations of $37.86 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. On average, sell-side analysts expect that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Large investors have recently made changes to their positions in the stock. GSA Capital Partners LLP increased its holdings in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock worth $1,474,000 after purchasing an additional 792,283 shares during the period. Geode Capital Management LLC increased its stake in shares of Karyopharm Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock valued at $1,125,000 after buying an additional 43,856 shares during the period. AQR Capital Management LLC raised its holdings in shares of Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock valued at $649,000 after acquiring an additional 622,194 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $494,000. Finally, FMR LLC lifted its stake in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company's stock worth $307,000 after acquiring an additional 76,510 shares during the period. 66.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Piper Sandler raised their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. Finally, Robert W. Baird reduced their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).